

Aetion

First published: 24/11/2022

Last updated: 16/07/2024

Institution

Other

Institution identification

PURI

<https://redirect.ema.europa.eu/resource/49942>

Institution ID

49942

Institution countries

Spain

Type of institution

Other

Institution website

<https://www.aetion.com>

ENCePP partner

Yes

Institution description

Aetion powers critical decisions with data science-driven technology and decision-ready real-world evidence. Founded by leading epidemiologists with decades of health outcomes research, Aetion informs health care's most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Aetion scientists, pharmacoepidemiologists and RWE experts enable the generation of decision-ready evidence at scale, for regulatory, policy, and pricing decisions - applications include Post-authorization safety studies (PASS), Post-authorization effectiveness studies (PAES), Drug Utilization studies (DUS) and Risk Evaluation and Mitigation Strategy (REMS). Aetion Evidence Platform® (AEP) is scientifically validated software that analyzes data from

the real world to produce transparent and rapid answers on safety and effectiveness across the drug lifecycle.

Institution details

Experience with collecting data directly from individual patients or respondents:

No

Interest in carrying out research that is funded by pharmaceutical companies:

Yes

Contact

Elizabeth Garry

Main

liz.garry@aetion.com